Author of

• 36267

  +

  P75 - Immunotherapy (Phase II/III Trials) - Misc. Topics (ID 248)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Immunotherapy (Phase II/III Trials)
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 36275

    +

    P75.08 - KDM5C Mutation Is Associated with Better Immunotherapy Outcomes in Non–Small Cell Lung Cancer (ID 2083)

    00:00 - 00:00  |  Presenting Author(s): Kun Wang
    • Abstract
    • Slides

    Introduction
    

    With the success of more and more clinical trials, lung cancer has entered the era of immunotherapy. Using PD-L1 expression and TMB as biomarker can effectively screen out the population benefiting from immunotherapy. However, these two biomarkers are not perfect. Even among biomarker-positive patients, the response rate was still low. Therefore, it is important to keep exploring the potential biomarkers for immunotherapy.

    Methods
    

    Lung cancer patient data from the public databases Riziv 240 and MSK were used as the discovery and validation cohorts for analysis, respectively. There were 240 patients in the Riziv cohort and 349 patients in the MSK cohort. All of these patients received immunotherapy and genetic testing. Fisher's exact test, log-rank test, and cox regression were used as statistical methods in IBM SPSS Statistic 21 and R 3.5.2.

    Results
    

    By comparing the genetic mutation information of the responders and the progressed patients in the Riziv cohort, a list of potential mutation genes was obtained, including KDM5C, AR, ARID1B and other genes. In the exploratory cohort, median progression-free survival was 13.2 months (95% CI, 4.4 to 22.0) in the KDM5C mutations group and 3.2 months (95% CI, 2.3 to 4.0) in the KDM5C wild-type group (hazard ratio for disease progression or death, 0.51; 95% CI, 0.24 to 1.09; P=0.07). In the validation cohort, the immunotherapy efficacy of patients with KDM5C mutations was better than that of KDM5C wild-type patients, with median overall survival 21 months (95% CI, 12.4 to 29.6) and 11 months (95% CI, 8.9 to 13.1) (hazard ratio for death, 0.63; 95% CI, 0.26 to 1.53).

    Conclusion
    

    KDM5C mutations are associated to better efficacy of immunotherapy and have potential value for guiding clinical practice.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.